Latest Conference Articles

Stay up to date on the latest oncology and nursing conferences.

Evolution of Frontline VEGF TKI/Immunotherapy Treatments Propels Field of Renal Cell Carcinoma

Evolution of Frontline VEGF TKI/Immunotherapy Treatments Propels Field of Renal Cell Carcinoma

August 10th 2022, 2:00pm

In a presentation at the 6th Annual School of Nursing Oncology™, Laura Wood, RN, MSN, OCN, highlights key nurse takeaways with VEGF TKI/immune checkpoint inhibitor therapy for patients with renal cell carcinoma.

Molecular Profiling Is a Necessity in Colorectal Cancer Treatment

Molecular Profiling Is a Necessity in Colorectal Cancer Treatment

August 9th 2022, 6:00pm

At the 6th Annual SONO meeting, Kelley A. Rone, DNP, RN, AGNP-C, reviewed evidence supporting molecular testing in patients with colorectal cancer.

Tislelizumab Maintains Superior Overall Survival Benefit Vs Docetaxel in Pretreated NSCLC

Tislelizumab Maintains Superior Overall Survival Benefit Vs Docetaxel in Pretreated NSCLC

August 9th 2022, 2:00pm

Patients with previously treated non–small cell lung cancer experienced a median overall survival of 16.9 months with second- or third-line tislelizumab vs 11.9 months with docetaxel.

Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

August 8th 2022, 6:00pm

Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor.

Nurses Adapt to New Hematology Advances and Approvals in Leukemia Treatment

Nurses Adapt to New Hematology Advances and Approvals in Leukemia Treatment

August 8th 2022, 4:00pm

Treatments options for various histologies of leukemia are expanding with FDA approvals for drugs such as the combination of ivosidenib/azacitidine and the CAR T-cell therapy brexucabtagene autoleucel.

Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC

Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC

August 5th 2022, 6:00pm

Beth Sandy, MSN, CRNP, discusses the application of 2 FDA approved drugs for patients with non–small cell lung cancer and an exon 20 insertion mutation.

Targeted Therapy Approvals Improve Outcomes, Expand Options for Patients With NSCLC

Targeted Therapy Approvals Improve Outcomes, Expand Options for Patients With NSCLC

August 4th 2022, 2:00pm

At the 6th Annual SONO meeting, Beth Sandy, MSN, CRNP, reviewed available treatment options for patients with identified driver mutations in non–small cell lung cancer.

Nurses Play Key Role in Facilitating Maintenance Therapy With PARP Inhibitors in Ovarian Cancer

Nurses Play Key Role in Facilitating Maintenance Therapy With PARP Inhibitors in Ovarian Cancer

August 2nd 2022, 6:00pm

Paula Anastasia, RN, MN, AOCN, discusses the value of germline testing and the role of maintenance PARP inhibitor therapy in optimized ovarian cancer treatment.

Nurse Navigators Can Help Alleviate Medical Distrust, Improve Clinical Trial Enrollment

Nurse Navigators Can Help Alleviate Medical Distrust, Improve Clinical Trial Enrollment

August 1st 2022, 6:00pm

Faith Mutale, CRNP, discusses the paradigm shift needed in oncology to address clinical trial enrollment hesitancy among African American patients with lung cancer.

Sarah Donahue Highlights Destiny-Breast04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast Cancer

Sarah Donahue Highlights Destiny-Breast04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast Cancer

August 1st 2022, 4:00pm

Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.